Study of AB-201 for advanced HER2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AB-201 for people with advanced stomach or gastroesophageal junction cancer that has HER2 protein and has not improved with standard treatments. The goal is to see if AB-201 can shrink tumors or slow the cancer's growth, and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old.
- You must have advanced (spread or cannot be removed by surgery) HER2-positive stomach or gastroesophageal junction cancer that has not responded to or you couldn't tolerate at least two previous treatments.
- You must have had a biopsy or surgery showing HER2 positivity within the last 3 years.
- You must have recovered from side effects of previous treatments, with at least 3 weeks since chemotherapy, 4 weeks since radiation or major surgery, and 4 weeks since immunotherapy.
- You must have adequate organ function (kidney, liver, blood counts) and a heart pumping ability of at least 50%.
- You must not have untreated or active brain metastases, uncontrolled infections, or significant heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
Hear when a new Malignant Neoplasm of Stomach, Unspecified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.